Company intelligence / Profile preview

PharmaNeuroBoost

Ownership: Private
Development stage: Other

Overview

PharmaNeuroBoost develops best-in-class CNS therapeutics using a proprietary technology that combines new chemical entities from existing drugs. Its lead program, PNB01 for major depression, received IND approval from the FDA and was cleared to start Phase III trials. The second program, PNB02 for schizophrenia, entered a proof-of-concept study after regulatory approval. The company also has additional pipeline assets targeting psychotic disorders and obsessive-compulsive disorder. Clinical results are not yet published beyond these milestones.

Therapeutic areas: Psychiatry
Modalities: Small moleculeCombination therapy
Industry: Biotech

Partnerships

IWT (Institute for the Promotion of Innovation by Science and Technology in Flanders)—funding support

Beyond the preview

Go deeper on PharmaNeuroBoost.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaNeuroBoost.

Explore the full profile